Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04231734
Other study ID # 19-05020213
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date April 2023
Est. completion date September 2026

Study information

Verified date August 2023
Source Weill Medical College of Cornell University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates adherence to a ketogenic diet in patients with low tumor burden, treatment-naïve mantle cell lymphoma.


Description:

This is a single-arm feasibility study to evaluate adherence to a ketogenic diet in patients with low tumor burden, treatment-naïve mantle cell lymphoma. Subjects will be evaluated for eligibility and baseline assessments prior to initiating the ketogenic diet during the screening period and/or prior to initiating the ketogenic diet on Day 1. Eligible subjects will receive study treatment which will consist of a daily ketogenic diet for up to 12 weeks (Day 1 through Day 84). Subjects will be monitored with weekly assessments of adherence to diet and effects on serum metabolic markers, tumor specimens, and body composition. After discontinuing the ketogenic diet, subjects will be followed for 28 days.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2026
Est. primary completion date April 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed diagnosis of mantle cell lymphoma - Age = 18 years - No prior systemic therapy for lymphoma - ECOG performance status = 2 - Required initial laboratory parameters: - Absolute neutrophil count (ANC) = 1000 cells/mm3 - Platelet count = 75,000 cells/mm3 - Calculated creatinine clearance = 30 ml/min by Cockcroft-Gault formula - Total bilirubin = 2.0 x ULN - AST/SGOT or ALT/SGPT = 3.0 x ULN - Understand and voluntarily sign an ICF prior to any study related assessments and procedures are conducted Exclusion Criteria: - Patients with blastoid histology - Patients with known or suspected central nervous system (CNS) involvement - Patients with a clear indication for treatment of lymphoma, including those with a tumor larger than 6 cm, more than 3 lymph nodes more than 3 cm, or constitutional symptoms - Active viral infection with HIV or hepatitis type B or C. Seropositive HBV patients are eligible if they are negative for HBV DNA by PCR and receive concomitant antiviral therapy during treatment and for additional six months after coming off study. - Active uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment) - Uncontrolled moderate to severe hypertriglyceridemia (TG>300 mg/dL). - Strong family history of hypertriglyceridemia and coronary artery disease. - Myocardial infarction within 6 months of cycle 1, day 1. [Subjects with a history of myocardial infarction between 6 and 12 months prior to cycle 1, day 1, who are asymptomatic and have had a negative cardiac risk assessment (treadmill stress test, nuclear medicine stress test, or stress echocardiogram) since the event, may participate]. - Symptomatic coronary artery disease (CAD), e.g., angina Canadian Class II-IV. In any patient in whom there is doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present. - An ECG recorded at screening showing evidence of cardiac ischemia (ST depression of = 2 mm, measured from isoelectric line to the ST segment). If in any doubt, the patient should have a stress imaging study and, if abnormal, angiography to define whether or not CAD is present. - Congestive heart failure (CHF) that meets New York Heart Association (NYHA) Class II to IV definitions and/or ejection fraction < 40% by multigated acquisition (MUGA) scan or < 50% by echocardiogram and/or magnetic resonance imaging (MRI). - Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication. - Patients requiring dual anti-platelets treatment for cardiac conditions or patients who are on anticoagulation for arterial or venous thrombosis. - Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. - Type I diabetes - Uncontrolled Type II diabetes mellitus (HbA1c> 7.5%). - Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin. - Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass. - Active complaints of dysphagia or odynophagia - Presence of a "feeding tube" (i.e. nasogastric tube, PEG, PEJ) - Participation in a specialty diet (e.g. Atkins, Weight Watchers, Best Life, Nutrisystem, South Beach, Jenny Craig, Paleo Diet, Zone, etc) or weight loss plan within 28 days prior to Cycle 1 of treatment. - Vegetarian or vegan eating habits. - An allergy or intolerance to egg, gluten, tree nuts, or milk protein. - History of serious or uncontrolled gout or hyperuricemia - Diagnosis of a seizure disorder. - Prior diagnosis of restless legs syndrome or a history of chronic muscle cramps, as defined as a period of at least 1 month where spontaneous cramping of the skeletal muscles occurred more than two-thirds of the days. - Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through at least 30 days after the last dose of trial treatment. - History of nephrolithiasis or nephrolithiasis incidentally discovered during CT screening. - Known selenium deficiency.

Study Design


Intervention

Other:
Ketogenic Diet
Prepared ketogenic meals, 3 per day for up to 12 weeks (Day 1 through Day 84)

Locations

Country Name City State
United States Weill Cornell Medicine New York New York

Sponsors (1)

Lead Sponsor Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects who adhere to ketogenic diet Number of subjects who adhere to ketogenic diet as defined by serum betahydroxybutyrate > 1.0 mM at 7 out of 11 timepoints 12 weeks
Secondary Number of subjects who achieve a partial or complete response Number of subjects who achieve a partial or complete response based on radiographic imaging using Lugano criteria for lymphoma response 12 weeks
Secondary Number of subjects who exhibit a significant change in fasting serum metabolic markers Fasting metabolic markers to be assessed for this outcome measure include insulin, glucose, and lipids Baseline, 16 weeks
Secondary Number of subjects who exhibit a significant change in serum mediators of inflammation Serum mediators of inflammation to be assessed for this outcome measure include high sensitivity C-reactive protein (hs-CRP), interleukin (IL)-6, tumor necrosis factor (TNF)-a, IL-1beta, and interferon (INF)-gamma. Baseline, 16 weeks
Secondary Number of subjects who exhibit a significant change in blood cell populations Blood cell populations will be assessed by performance of unbiased expression analysis (RNA-Seq) from blood cell populations, and High-Dimensional Single-Cell Mass Cytometry (CyTOF) analysis of peripheral blood cells Baseline, 16 weeks
Secondary Change in body composition as measured by difference in ideal body weight and actual body weight at the end of study compared to baseline Baseline, 16 weeks
Secondary Number of subjects who complete quality of life questionnaires at required timepoints Quality of life questionnaire to be used for this outcome measure is EORTC-C30 16 weeks
Secondary Effect of ketogenic diet on gut microbiome Change in proportion of most common gut bacteria identified by DNA analysis of stool samples 12 weeks
Secondary Rate of recruitment Percentage of subjects screened for the trial who eventually enroll in the trial 1 year
Secondary Subject adherence to scheduled laboratory assessments Percentage of laboratory assessments successfully attended by subjects 12 weeks
Secondary Subject adherence to meal assessments Percentage of meal assessments successfully completed by subjects 12 weeks
Secondary Rate of attrition Percentage of subjects enrolled who drop out before trial completion 12 weeks
Secondary Rate of daily ketosis Percentage of days in ketosis as defined by positive ketones results on ketostix 12 weeks
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Recruiting NCT05976763 - Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Phase 3
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Recruiting NCT05471843 - Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Phase 1/Phase 2
Recruiting NCT05076097 - A Study of OLR in First-line Treatment of Mantle Cell Lymphoma Phase 2
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03891355 - Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL Phase 2
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT01665768 - Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma Phase 2
Completed NCT01437709 - Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant Phase 2
Completed NCT00963534 - Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. Phase 1/Phase 2
Completed NCT00921414 - Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Phase 3
Withdrawn NCT00541424 - Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma N/A
Completed NCT01456351 - Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Phase 3
Completed NCT01851551 - Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL Phase 1/Phase 2
Completed NCT03295240 - The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Early Phase 1